- Home
- KZIA vs APVO Comparison
KZIA vs APVO Comparison
Compare KZIA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- APVO
- Stock Information
- Founded
- KZIA 1994
- APVO 2016
- Country
- KZIA Australia
- APVO United States
- Employees
- KZIA N/A
- APVO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- APVO Health Care
- Exchange
- KZIA Nasdaq
- APVO Nasdaq
- Market Cap
- KZIA 6.0M
- APVO 5.4M
- IPO Year
- KZIA 1999
- APVO N/A
- Fundamental
- Price
- KZIA $0.77
- APVO $1.90
- Analyst Decision
- KZIA Strong Buy
- APVO Strong Buy
- Analyst Count
- KZIA 2
- APVO 1
- Target Price
- KZIA $11.50
- APVO $296.00
- AVG Volume (30 Days)
- KZIA 334.9K
- APVO 1.2M
- Earning Date
- KZIA 04-11-2025
- APVO 05-07-2025
- Dividend Yield
- KZIA N/A
- APVO N/A
- EPS Growth
- KZIA N/A
- APVO N/A
- EPS
- KZIA N/A
- APVO N/A
- Revenue
- KZIA $1,655,324.00
- APVO N/A
- Revenue This Year
- KZIA N/A
- APVO N/A
- Revenue Next Year
- KZIA N/A
- APVO N/A
- P/E Ratio
- KZIA N/A
- APVO N/A
- Revenue Growth
- KZIA 248000.00
- APVO N/A
- 52 Week Low
- KZIA $0.76
- APVO $0.94
- 52 Week High
- KZIA $15.80
- APVO $180.19
- Technical
- Relative Strength Index (RSI)
- KZIA 35.51
- APVO 51.31
- Support Level
- KZIA $0.76
- APVO $0.94
- Resistance Level
- KZIA $1.05
- APVO $3.61
- Average True Range (ATR)
- KZIA 0.08
- APVO 0.53
- MACD
- KZIA -0.00
- APVO 0.02
- Stochastic Oscillator
- KZIA 3.84
- APVO 54.27
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.